MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14656566.2022.2102418

Медицинская библиотека · Expert opinion on pharmacotherapy · 2022

Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date.

Spasovski Goce, Trajceska Lada, Rambabova-Bushljetik Irena

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Although early rejection episodes are successfully controlled, the problem of unrecognized production of de novo anti-HLA antibodies and associated chronic rejection still persists.

AREAS COVERED: In addition to the standard induction and maintenance therapy, we present a couple of new drugs as induction (Alemtuzumab), CNI-free protocol (Belatacept, Sirolimus, and Everolimus), and maintenance treatment in transplant patients with various types of malignancies (T cell-targeted immunomodulators blocking the immune checkpoints CTLA-4 and PD1/PDL1) and TMA (aHUS)-eculizumab and IL6 receptor antagonists in antibody-mediated rejection (AMR).

EXPERT OPINION: There are a couple of issues still preventing improvement in kidney transplant long-term outcomes with current and anticipated future immunosuppression: patients more susceptible to infection and CNI nephrotoxicity in kidneys obtained from elderly donors and highly sensitized patients with limited chances to get appropriate kidney and a higher risk for late AMR. A lower rate of CMV/BK virus infections has been observed in everolimus-treated patients. Belatacept use has been justified only in EBV-seropositive kidney transplants due to the increased risk of PTLD. Eculizumab upon recurrence of aHUS is a sole cost-effective option. A new IL-6 blocking drug (clazakizumab/tocilizumab) is a promising option for prevention/treatment of AMR. Clinical experience in tailoring immunosuppression for improving as long as possible graft and patient survival is inevitable.

Для цитирования: Spasovski Goce, Trajceska Lada, Rambabova-Bushljetik Irena. Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date.. Expert opinion on pharmacotherapy. 2022. DOI: 10.1080/14656566.2022.2102418.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.